TaiGen Biotechnology
Taipei, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage pharma company developing novel small molecule therapies for infections and cancer.
Infectious DiseaseOncology
Technology Platform
Structure-based drug design platform for discovering and optimizing novel small molecule therapeutics.
Opportunities
Potential to address antibiotic-resistant infections and niche oncology targets with its novel compounds.
Risk Factors
High binary risk associated with late-stage clinical trial outcomes for its lead candidates.
Competitive Landscape
Competes with global pharma in niche infectious disease areas and faces crowded competition in oncology small molecule development.